Steffen CL et al. Identification of an H-Ras nanocluster disrupting peptide. Communications Biology. 7, 837 (2024).
Link→
Armenteros JJA et al. Multi-omics analysis reveals drivers of loss of β-cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study. Diabetes/Metabolism Research and Reviews. 2024: 40:e3833.
Link→
Momeny M et al. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Molecular Medicine. 2024 June 17.
Link→
Starskaia I. Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies. Nature Communications. 2024 May 7;15(1):3810.
Pubmed→
Kalim UU et al. A proximal enhancer regulates RORA expression during early human Th17 cell differentiation. Journal of Clinical Immunology. 2024 May 22:264:110261.
Pubmed→
Andrabi SBA et al. Long noncoding RNA LIRIL2R modulates FOXP3 levels and suppressive function of human CD4+ regulatory T cells by regulating IL2RA. Proceedings of the National Academy of Sciences of the United States of America. 2024 Jun 4;121(23).
Pubmed→
Bhattacharya D & al. Single-cell characterisation of tissue homing CD4 + and CD8 + T cell clones in immune-mediated refractory arthritis. Molecular Medicine. 2024, 30, 48.
Link →
Koskinen LM & al. Spatial Engineering of Mammary Epithelial Cell Cultures with 3D Bioprinting Reveals Growth Control by Branch Point Proximity. Journal of Mammary Gland Biology and Neoplasia. 2024 Feb 28;29(1):5.
Link →
Buchacher T & al. PIM kinases regulate early human Th17 cell differentiation. Cell Reports. 2023 Dec 26;42(12):113469.
Link →
Andrabi et al. HIC1 interacts with FOXP3 multi protein complex: Novel pleiotropic mechanisms to regulate human regulatory T cell differentiation and function. Immunology Letters. 2023 Nov:263:123-132.
Link →
M K Hirvonen et al. Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes. Scientific Reports. 2023 Sep 24;13(1):15941.
Link →
Nagelli S et al. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. Trends in Cancer. 2023 Oct 2.
Link →
Oras A et al. Profiling of peripheral blood B-cell transcriptome in children who developed coeliac disease in a prospective study.
Heliyon. 2023 Jan 21;9(2):e13147.
Pubmed →
Brunell A E et al. Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. Frontiers in Immunology. 2023 Apr 14;14:1151632.
Pubmed →
Suomi T et al. Gene expression signature predicts rate of type 1 diabetes progression.
EBioMedicine. 2023 Jun;92:104625.
Pubmed →
Moulder R et al. Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory. Diabetologia. 2023 Nov;66(11):1983-1996.
Pubmed →
Lamichhane S et al. Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children. Frontiers in Endocrinology. 2023 Sep 6;14:1211015.
Pubmed →
Hirvonen M K et al. Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes. Scientific Reports. 2023 Sep 24;13(1):15941.
Pubmed →
Cazzoli R et al. Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition. Cell Reports. 2023 Jun 7;42(6):112616. Online ahead of print.
Pubmed →
Örd T et al. Dissecting the polygenic basis of atherosclerosis via disease-associated cell state signatures. American Journal of Human Genetics. 2023.Apr 11;S0002-9297(23)00097-6.
Pubmed →
Westermarck J. Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?. Molecular Oncology. 2023. Feb 28.
Pubmed →
Huuhtanen J. et al. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. Journal of Clinical Investigation. 2023. Jan 31;e164809.
Pubmed →
Aakula A et al. RAS and PP2A activities converge on epigenetic gene regulation. Life Science Alliance. 2023 Mar 1;6(5):e202301928.
Pubmed →
Pavic K et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications. 2023 Feb 28;14(1):1143.
Pubmed →